Online inquiry

IVTScrip™ mRNA-Anti-CD274, MPDL3280A(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ12250MR)

This product GTTS-WQ12250MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets CD274 gene. The antibody can be applied in Solid tumors, Renal cell carcinoma (RCC) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001267706.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 29126
UniProt ID Q9NZQ7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD274, MPDL3280A(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ12250MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ14111MR IVTScrip™ mRNA-Anti-NGF, aNGF75(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA aNGF75
GTTS-WQ4770MR IVTScrip™ mRNA-Anti-TNFSF13B, BR3-Fc(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA BR3-Fc
GTTS-WQ13608MR IVTScrip™ mRNA-Anti-APP, R1450(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA R1450
GTTS-WQ8653MR IVTScrip™ mRNA-Anti-CD38, HuMax-CD38(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA HuMax-CD38
GTTS-WQ14512MR IVTScrip™ mRNA-Anti-IL6R, SA-237(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA SA-237
GTTS-WQ631MR IVTScrip™ mRNA-Anti-IL9, 7F3com-2H2(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA 7F3com-2H2
GTTS-WQ15913MR IVTScrip™ mRNA-Anti-IL1B, XOMA 052(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA XOMA 052
GTTS-WQ1055MR IVTScrip™ mRNA-Anti-TNFRSF10B, ABBV-621(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ABBV-621
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW